Table 3.
Comparison between HBcAb/HBsAb-positive vs. HBcAb-positive/HBsAb-negative.
| Study population | HBcAb+/HBsAb+ (n = 49) | HBcAb+/HBsAb−. (n = 36) | P-value |
|---|---|---|---|
| Age, years, median (IQR) | 48 (39–55) | 47 (39–55) | 0,71 |
| Duration of cART, months, median (IQR) | 70 (34–96,5) | 56 (34–88) | 0,73 |
| AST, UI/L, median (IQR) | 21 (17–28) | 25 (20–45) | 0,04 |
| ALT, UI/L, median (IQR) | 31 (26–42) | 33 (22,5–53) | 0,93 |
| Platelet count, 10^6/µL, median (IQR) | 192 (127–226) | 176 (119–238) | 0,91 |
| Flair of transaminases, median (IQR) | 30 (61%) | 26 (72%) | 0,35 |
| HCV-RNA-positive, n. (%) | 0 (0) | 1 (2,7%) | nc |
| Baseline CD4+, cell/mmc, median (IQR) | 193 (83–363) | 159 (58–280) | 0,25 |
| Pre-cART CD4+ cell/mmc, median (IQR) | 180 (68–302) | 159 (45–243) | 0,31 |
| Pre-cART HIV cp/mL median (IQR) | 102765 (41600–198989) | 355996 (49091–405087) | 0,24 |
| Undetectability at 6th month, median (IQR) | 32 (65,3%) | 18 (51,4%) | 0,26 |
| AIDS-related events, Yes/No, n. (%) | 17 (34,7%) | 18 (50%) | 0,15 |
| Non-AIDS related events, Yes/No, n. (%) | 31 (63,2%) | 17 (47,2%) | 0,14 |
| Antiretroviral drugs, n. (%): | |||
| -Lamivudine | 7 (19,4%) | 7 (14,3%) | 0,36 |
| -Tenofovir/TAF | 37 (75,5%) | 25 (69,4%) | 0,35 |
| -No anti-HBV agent | 5 (10,2%) | 4 (11,1%) | NC |
| >1 year without anti-HBV agent, n. (%) | 7 (14,3%) | 5 (14,3%) | NC |
| HIV VR, median (IQR) | 6 (12,2%) | 12 (35,3%) | 0,01 |
| HIV VB, median (IQR) | 34 (69,4%) | 28 (82,3%) | 0,18 |
IDU: injecting drug users; cART: combined antiretroviral therapy; AST: aspartate aminotransferase; ALT: alanine aminotransferase; TAF: Tenofovir alafenamide; VR: virological rebound; VB: HIV viral blips.